ZD4054

From WikiMD.org
Jump to navigation Jump to search

ZD4054

ZD4054 (/zɛd fɔːr oʊ faɪv fɔːr/), also known as Zibotentan, is a specific endothelin receptor antagonist that was under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Etymology

The name ZD4054 is a systematic code assigned by the developing company, AstraZeneca. The prefix 'ZD' is commonly used in the naming of drugs developed by this company. The numbers '4054' do not have a known specific meaning.

Mechanism of Action

ZD4054 works by blocking the endothelin-1 receptors (ET_A). Endothelin-1 is a potent vasoconstrictor and has been implicated in the progression of cancer. By blocking these receptors, ZD4054 inhibits the action of endothelin-1, potentially slowing the growth and spread of cancer cells.

Clinical Trials

ZD4054 underwent Phase II and III clinical trials for the treatment of mCRPC. However, the drug did not meet its primary endpoint of improving overall survival in patients with mCRPC and development was discontinued.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski